Valuation: Alkermes plc

Market Cap 8.31B 7.22B 6.74B 6.19B 11.67B 792B 11.87B 79.5B 31.14B 395B 31.21B 30.52B 1,303B P/E 2026 *
-97.2x
P/E 2027 * 68.1x
Enterprise Value 9.05B 7.87B 7.35B 6.74B 12.72B 863B 12.94B 86.62B 33.92B 430B 34.01B 33.25B 1,419B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 4.62x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week-6.07%
Current month+1.10%
1 month-9.25%
3 months+48.38%
6 months+43.69%
Current year+77.02%
1 week 47.66
Extreme 47.66
50.72
1 month 47.66
Extreme 47.66
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Compliance Officer

-2,034 0.0012%
1/7/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
12/6/26 Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%-6.07%+86.55%+79.26% 8.31B
-0.36%+0.14%-2.06%+14.33% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
-0.62%+1.23%+2.76%+15.05% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -1.04%-1.20%+62.28%+84.95% 25.56B
Weighted average by Cap. -1.16%-0.05%+75.94%+102.76%

Financials

2026 *2027 *
Net sales 1.82B 1.59B 1.48B 1.36B 2.56B 174B 2.61B 17.46B 6.84B 86.74B 6.85B 6.7B 286B 1.94B 1.69B 1.58B 1.45B 2.73B 185B 2.78B 18.6B 7.29B 92.43B 7.3B 7.14B 305B
Net income -89.92M -78.15M -72.96M -66.98M -126M -8.57B -128M -860M -337M -4.27B -338M -330M -14.1B 120M 105M 97.6M 89.6M 169M 11.47B 172M 1.15B 451M 5.72B 452M 442M 18.86B
Net Debt 744M 647M 604M 554M 1.04B 70.91B 1.06B 7.12B 2.79B 35.36B 2.79B 2.73B 117B 670M 582M 544M 499M 941M 63.85B 957M 6.41B 2.51B 31.84B 2.52B 2.46B 105B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
03/08/26 USD 49.53 +1.10% 1,835,762
31/07/26 USD 48.99 -2.08% 1,624,487
30/07/26 USD 50.03 +3.50% 2,303,338
29/07/26 USD 48.34 -4.28% 4,149,635
28/07/26 USD 50.50 -4.23% 2,875,996
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.53USD
Average target price
56.00USD
Spread / Average Target
+13.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock